Corresponding author:

ARTICLE Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

Shuiying Hu
Hongmei Niu
Hiroto Inaba
Shelley Orwick
Charles Rose
John C. Panetta
Shengping Yang
Stanley Pounds
Yiping Fan

October 2016

Acute myeloid leukemia (AML) is a genetically heterogeneous form of leukemia. Leukemic cells in many...

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar, I.M.E.
Timmer-Bonte, J.N.H.
Burger, D.M.
Graaf, W.T.A. van der
Herpen, C.M.L. van

January 2010

Contains fulltext : 87630.pdf (publisher's version ) (Closed access)BACKGROUND: Th...

Article Reference

Jakob R. Passweg
Thomas Pabst
Sabine Blum
Mario Bargetzi
Qiyu Li
Dominik Heim
Georg Stussi
Michael Gregor
Leda Leoncini
Rine Meyer-monard
Peter Brauchli
Yves Chal

September 2016

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07) P...

syndrome: safety, pharmacokinetics

Daniel J. Deangelo
Richard M. Stone
Mark L. Heaney
Stephen D. Nimer
Ronald L. Paquette
Rebecca B. Klisovic
Michael A. Caligiuri
Michael R. Cooper
Jean-michel Lecerf
Michael D. Karol
Shihong Sheng
Nick Holford
Peter T. Curtin
Brian J. Druker
Michael C. Heinrich

September 2016

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute m...

Corresponding Author:

Alireza Eghtedar
Srdan Verstovsek
Zeev Estrov
Jan Burger
Carol Bivins
Stefan Faderl
Ra Ferrajoli
Solly George
Peggy A Scherle
Robert C Newton
Hagop M
Kantarjian Farhad Ravandi
Farhad Ravandi Md

September 2016

Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, includ...

Running title: Efficacy of volasertib in preclinical models of AML Corresponding author:

Dorothea Rudolph
Maria Antonietta Impagnatiello
Claudia Blaukopf
Christoph Sommer
Daniel W. Gerlich
Ulrike Tontsch-grunt
Andreas Wernitznig
Fabio Savarese
Lena Geiselmann
Markus Reschke
Pilar Garin-chesa
Jürgen Moll
Günther R
Norbert Kraut
Dorothea Rudolph Phd
Boehringer Ingelheim
Rcv Gmbh
Co Kg

January 2016

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...

Corresponding author:

Nina D. Wagner-johnston
Brad S. Kahl

September 2016

• This clinical study assessed idelalisib, a selective PI3Kδ inhibitor, in 40 patients with relapsed...

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Lowenberg, B.
Muus, P.
Ossenkoppele, G.
Rousselot, P.
Cahn, J.Y.
Ifrah, N.
Martinelli, G.
Amadori, S.
Berman, E.
Sonneveld, P.
Jongen-Lavrencic, M.
Rigaudeau, S.
Stockman, P.
Goudie, A.
Faderl, S.
Jabbour, E.
Kantarjian, H.

January 2011

Item does not contain fulltextThe primary objective of this 2-part phase 1/2 study was to determine ...

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

Chiarini, Francesca
Evangelisti, Camilla
Martelli, Alberto M.
McCubrey, James A.
NC DOCKS at East Carolina University

January 2010

Table of contents for this issue and main article; The phosphatidylinositol 3-kinase (PI3K)/Akt/mamm...

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld, P.
Hajek, R.
Nagler, A.
Spencer, A.
Blade, J.
Robak, T.
Zhuang, S.H.
Harousseau, J.L.
Orlowski, R.Z.
Raymakers, R.A.P.

January 2008

Item does not contain fulltextBACKGROUND: Recently, the authors reported improved time to disease pr...

The clinical development of FLT3 inhibitors in acute myeloid leukemia

Knapper, Steven

January 2011

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at high frequ...

ORIGINAL ARTICLE Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry

Georg Theiler
S. Burgstaller
J. Thaler
M. Girschikofsky
S. Machherndl-sp
W. Linkesch :g. Theiler
R. Stauder
M. Pfeilstocker
M. Schreder

January 2014

# The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Data o...

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).

Amadori, S.
Suciu, S.
Selleslag, D.
Stasi, R.
Alimena, G.
Baila, L.
Rizzoli, V.
Borlenghi, E.
Gaidano, G.
Magro, D.
Torelli, G.
Muus, P.
Venditti, A.
Cacciola, E.
Lauria, F
Vignetti, M.
Witte, T.J.M. de

January 2010

Contains fulltext : 89504.pdf (publisher's version ) (Closed access)This study com...

Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab

Afifi, Salma
Michaels, Alexander T
Lesokhin, Alexander

July 2016

OBJECTIVE: To review the clinical pharmacology, efficacy, and safety of daratumumab and elotuzumab f...

Azacitidine in AML: a treatment option?

Huls, G.A.

January 2015

Contains fulltext : 151961.pdf (publisher's version ) (Closed access)In this issue...

ARTICLE Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

Shuiying Hu
Hongmei Niu
Hiroto Inaba
Shelley Orwick
Charles Rose
John C. Panetta
Shengping Yang
Stanley Pounds
Yiping Fan

October 2016

Acute myeloid leukemia (AML) is a genetically heterogeneous form of leukemia. Leukemic cells in many...

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar, I.M.E.
Timmer-Bonte, J.N.H.
Burger, D.M.
Graaf, W.T.A. van der
Herpen, C.M.L. van

January 2010

Contains fulltext : 87630.pdf (publisher's version ) (Closed access)BACKGROUND: Th...

Article Reference

Jakob R. Passweg
Thomas Pabst
Sabine Blum
Mario Bargetzi
Qiyu Li
Dominik Heim
Georg Stussi
Michael Gregor
Leda Leoncini
Rine Meyer-monard
Peter Brauchli
Yves Chal

September 2016

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07) P...

syndrome: safety, pharmacokinetics

Daniel J. Deangelo
Richard M. Stone
Mark L. Heaney
Stephen D. Nimer
Ronald L. Paquette
Rebecca B. Klisovic
Michael A. Caligiuri
Michael R. Cooper
Jean-michel Lecerf
Michael D. Karol
Shihong Sheng
Nick Holford
Peter T. Curtin
Brian J. Druker
Michael C. Heinrich

September 2016

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute m...

Corresponding Author:

Alireza Eghtedar
Srdan Verstovsek
Zeev Estrov
Jan Burger
Carol Bivins
Stefan Faderl
Ra Ferrajoli
Solly George
Peggy A Scherle
Robert C Newton
Hagop M
Kantarjian Farhad Ravandi
Farhad Ravandi Md

September 2016

Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, includ...

Running title: Efficacy of volasertib in preclinical models of AML Corresponding author:

Dorothea Rudolph
Maria Antonietta Impagnatiello
Claudia Blaukopf
Christoph Sommer
Daniel W. Gerlich
Ulrike Tontsch-grunt
Andreas Wernitznig
Fabio Savarese
Lena Geiselmann
Markus Reschke
Pilar Garin-chesa
Jürgen Moll
Günther R
Norbert Kraut
Dorothea Rudolph Phd
Boehringer Ingelheim
Rcv Gmbh
Co Kg

January 2016

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...

Corresponding author:

Nina D. Wagner-johnston
Brad S. Kahl

September 2016

• This clinical study assessed idelalisib, a selective PI3Kδ inhibitor, in 40 patients with relapsed...

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Lowenberg, B.
Muus, P.
Ossenkoppele, G.
Rousselot, P.
Cahn, J.Y.
Ifrah, N.
Martinelli, G.
Amadori, S.
Berman, E.
Sonneveld, P.
Jongen-Lavrencic, M.
Rigaudeau, S.
Stockman, P.
Goudie, A.
Faderl, S.
Jabbour, E.
Kantarjian, H.

January 2011

Item does not contain fulltextThe primary objective of this 2-part phase 1/2 study was to determine ...

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

Chiarini, Francesca
Evangelisti, Camilla
Martelli, Alberto M.
McCubrey, James A.
NC DOCKS at East Carolina University

January 2010

Table of contents for this issue and main article; The phosphatidylinositol 3-kinase (PI3K)/Akt/mamm...

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld, P.
Hajek, R.
Nagler, A.
Spencer, A.
Blade, J.
Robak, T.
Zhuang, S.H.
Harousseau, J.L.
Orlowski, R.Z.
Raymakers, R.A.P.

January 2008

Item does not contain fulltextBACKGROUND: Recently, the authors reported improved time to disease pr...

The clinical development of FLT3 inhibitors in acute myeloid leukemia

Knapper, Steven

January 2011

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at high frequ...

ORIGINAL ARTICLE Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry

Georg Theiler
S. Burgstaller
J. Thaler
M. Girschikofsky
S. Machherndl-sp
W. Linkesch :g. Theiler
R. Stauder
M. Pfeilstocker
M. Schreder

January 2014

# The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Data o...

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).

Amadori, S.
Suciu, S.
Selleslag, D.
Stasi, R.
Alimena, G.
Baila, L.
Rizzoli, V.
Borlenghi, E.
Gaidano, G.
Magro, D.
Torelli, G.
Muus, P.
Venditti, A.
Cacciola, E.
Lauria, F
Vignetti, M.
Witte, T.J.M. de

January 2010

Contains fulltext : 89504.pdf (publisher's version ) (Closed access)This study com...

Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab

Afifi, Salma
Michaels, Alexander T
Lesokhin, Alexander

July 2016

OBJECTIVE: To review the clinical pharmacology, efficacy, and safety of daratumumab and elotuzumab f...

Azacitidine in AML: a treatment option?

Huls, G.A.

January 2015

Contains fulltext : 151961.pdf (publisher's version ) (Closed access)In this issue...

ARTICLE Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

Shuiying Hu
Hongmei Niu
Hiroto Inaba
Shelley Orwick
Charles Rose
John C. Panetta
Shengping Yang
Stanley Pounds
Yiping Fan

October 2016

Acute myeloid leukemia (AML) is a genetically heterogeneous form of leukemia. Leukemic cells in many...

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar, I.M.E.
Timmer-Bonte, J.N.H.
Burger, D.M.
Graaf, W.T.A. van der
Herpen, C.M.L. van

January 2010

Contains fulltext : 87630.pdf (publisher's version ) (Closed access)BACKGROUND: Th...

Article Reference

Jakob R. Passweg
Thomas Pabst
Sabine Blum
Mario Bargetzi
Qiyu Li
Dominik Heim
Georg Stussi
Michael Gregor
Leda Leoncini
Rine Meyer-monard
Peter Brauchli
Yves Chal

September 2016

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07) P...

Corresponding author:

Abstract

Extracted data

Corresponding author:

Abstract

Extracted data

Topics

Related items

Topics

Related items